JHVEPhoto Eli Lilly ( NYSE: LLY ) said that data from two phase 3 studies found that patients treated with Omvoh (mirikizumab) saw long-term remission of ulcerative colitis or Crohn's disease. Results from the LUCENT-3 study found that after up to three years of.